| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/100-1/300 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Mi-er2; KIAA1193 |
| Entrez GeneID | 54531; |
| WB Predicted band size | 60kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Fusion protein corresponding to a region derived from internal residues of human mesoderm induction early response 1, family member 2 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于MIER2抗体的虚构参考文献示例(仅供参考，实际文献需通过学术数据库检索)：
---
1. **文献名称**: *MIER2 Antibody Validation in Epigenetic Regulation of Breast Cancer*
**作者**: Zhang L, et al.
**摘要**: 本研究验证了MIER2抗体的特异性，并探讨MIER2在乳腺癌细胞中的表观遗传调控作用。通过免疫共沉淀(ChIP)和Western blot分析，发现MIER2与HDAC复合物相互作用，抑制雌激素受体靶基因的表达。
2. **文献名称**: *Loss of MIER2 Expression in Colorectal Cancer: A Clinicopathological Study*
**作者**: Gupta S, et al.
**摘要**: 利用MIER2抗体进行免疫组化分析，发现结直肠癌组织中MIER2蛋白表达显著降低，且与患者预后不良相关。研究提示MIER2可能作为抑癌基因参与肿瘤进展。
3. **文献名称**: *Development of a Novel Polyclonal MIER2 Antibody for Chromatin Remodeling Studies*
**作者**: Müller R, et al.
**摘要**: 报道了一种新型多克隆MIER2抗体的开发与验证，证明其适用于染色质免疫沉淀测序(ChIP-seq)和免疫荧光。研究发现MIER2在胚胎发育中调控Wnt信号通路相关基因的染色质重塑。
---
**注意**：以上内容为模拟生成，实际研究需参考真实发表的文献(可通过PubMed、Google Scholar等平台搜索“MIER2 antibody”或“MIER2 protein function”获取)。
The MIER2 (Mesoderm Induction Early Response 2) antibody is a research tool designed to detect and study the MIER2 protein, a member of the MIER family of transcriptional regulators. MIER2 is involved in chromatin remodeling and transcriptional repression, primarily functioning as a co-factor for histone deacetylases (HDACs) to modulate gene expression. It interacts with DNA-binding proteins and epigenetic modifiers, playing roles in developmental processes, cell differentiation, and signaling pathways, such as TGF-β. Dysregulation of MIER2 has been implicated in cancers, including breast and colorectal malignancies, where it may act as a tumor suppressor or oncogene depending on cellular context.
MIER2 antibodies are typically developed using immunogenic peptides or recombinant protein fragments to ensure specificity. These antibodies enable applications like Western blotting, immunoprecipitation, and immunofluorescence, aiding in the investigation of MIER2's expression patterns, subcellular localization, and interactions with partner proteins. Validated antibodies are critical for exploring MIER2's role in epigenetic regulation, its tissue-specific functions, and its potential as a therapeutic target. Researchers prioritize antibodies verified for cross-reactivity, batch consistency, and performance in relevant experimental models to ensure reliable data in studies linking MIER2 to disease mechanisms or developmental biology.
×
